K

PriceKiniksa Pharmaceuticals

KNSA

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Historical stock price chart and annual return over the past years

17%

5 years

% Total

KNSA
3%

5 years

Annual Return

KNSA